Cited by

• Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey.

  Lou J, Huang J, Wang Z, Wen B, Tu C, Huang W, Zhai Z, Du X. Lou J, et al. Patient Prefer Adherence. 2018 Jun 15;12:1025-1032. doi: 10.2147/PPA.S163393. eCollection 2018. Patient Prefer Adherence. 2018. PMID: 29942119 Free PMC article.
• JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

  Springuel L, Renauld JC, Knoops L. Springuel L, et al. Haematologica. 2015 Oct;100(10):1240-53. doi: 10.3324/haematol.2015.132142. Haematologica. 2015. PMID: 26432382 Free PMC article. Review.
• Smooth muscle hyperplasia due to loss of smooth muscle α-actin is driven by activation of focal adhesion kinase, altered p53 localization and increased levels of platelet-derived growth factor receptor-β.

  Papke CL, Cao J, Kwartler CS, Villamizar C, Byanova KL, Lim SM, Sreenivasappa H, Fischer G, Pham J, Rees M, Wang M, Chaponnier C, Gabbiani G, Khakoo AY, Chandra J, Trache A, Zimmer W, Milewicz DM. Papke CL, et al. Hum Mol Genet. 2013 Aug 1;22(15):3123-37. doi: 10.1093/hmg/ddt167. Epub 2013 Apr 15. Hum Mol Genet. 2013. PMID: 23591991 Free PMC article.
• Prior exposure to imatinib does not impact outcome of allogeneic hematopoietic transplantation for chronic myeloid leukemia patients: a single-center experience in china.

  Shen K, Liu Q, Sun J, Jiang Q, Ye Y, Huang H, Meng F, Zhou Y, Yang M. Shen K, et al. Int J Clin Exp Med. 2015 Feb 15;8(2):2495-505. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 25932195 Free PMC article.
• Inhibition of an Erythrocyte Tyrosine Kinase with Imatinib Prevents Plasmodium falciparum Egress and Terminates Parasitemia.

  Kesely KR, Pantaleo A, Turrini FM, Olupot-Olupot P, Low PS. Kesely KR, et al. PLoS One. 2016 Oct 21;11(10):e0164895. doi: 10.1371/journal.pone.0164895. eCollection 2016. PLoS One. 2016. PMID: 27768734 Free PMC article.